CRON Cronos Group Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1656472 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY55.8%
TTM net income YoY60.2%
TTM EPS YoY60.0%
Revenue 3-yr CAGR34.2%
Net income 3-yr CAGR—
Margins
Gross margin46.6%
Operating margin3.4%
Net margin28.0%
FCF margin31.7%
EBITDA margin7.4%
Returns
ROE5.4%
ROA4.9%
ROIC (approx.)1.5%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets6.1%
Debt / equity0.00x
Current ratio12.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue7.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $146.59M | $117.61M | $87.24M | $86.75M | $64.56M |
| Gross profit | $62.76M | $25.20M | $11.91M | $15.44M | -$17.59M |
| R&D expense | $4.45M | $4.23M | $5.84M | $13.13M | $21.84M |
| SG&A expense | $42.00M | $46.51M | $49.48M | $67.67M | $90.92M |
| Operating income | -$17.39M | -$76.53M | -$84.80M | -$111.43M | -$291.97M |
| Interest expense | — | — | — | $13,000 | $27,000 |
| Pretax income | -$17.12M | $36.59M | -$73.67M | -$121.00M | -$128.51M |
| Income tax | -$14.19M | -$3.44M | -$3.23M | $34.17M | -$431,000 |
| Net income | -$9.45M | $41.08M | -$73.96M | -$168.73M | -$396.11M |
| EBITDA | -$3.16M | -$67.19M | -$76.69M | -$98.31M | -$276.57M |
| EPS (basic) | -0.02 | 0.11 | -0.19 | -0.45 | -1.07 |
| EPS (diluted) | -0.02 | 0.11 | -0.19 | -0.45 | -1.07 |
| Weighted avg. shares (diluted) | 383.47M | 385.56M | 380.96M | 376.96M | 370.39M |
| Balance sheet | |||||
| Cash & equivalents | $791.79M | $858.80M | $669.29M | $764.64M | $886.97M |
| Short-term investments | $40.00M | $0 | $192.24M | $113.08M | $117.68M |
| Receivables | $34.10M | $15.46M | $13.98M | $23.11M | $22.07M |
| Inventory | $46.75M | $33.15M | $30.50M | $37.56M | $32.80M |
| Current assets | $944.09M | $936.11M | $933.31M | $960.16M | $1.08B |
| PP&E, net | $145.87M | $133.19M | $59.47M | $60.56M | $74.07M |
| Goodwill | $66.48M | $63.45M | $1.06M | $1.03M | $1.10M |
| Intangibles | $8.89M | $11.26M | $21.08M | $26.70M | $18.08M |
| Total assets | $1.20B | $1.17B | $1.14B | $1.21B | $1.40B |
| Current liabilities | $48.19M | $49.70M | $41.40M | $68.12M | $54.37M |
| Total liabilities | $54.18M | $55.33M | $44.14M | $72.05M | $63.46M |
| Shareholders' equity | $1.09B | $1.06B | $1.10B | $1.14B | $1.34B |
| Shares outstanding | 381.59M | 382.53M | 381.30M | 380.58M | 374.95M |
| Cash flow statement | |||||
| Operating cash flow | $25.87M | $18.84M | -$42.84M | -$88.95M | -$153.62M |
| Capital expenditure | $25.72M | $12.41M | $2.50M | $3.45M | $11.14M |
| Free cash flow | $149,000 | $6.43M | -$45.34M | -$92.40M | -$164.76M |
| Investing cash flow | -$76.56M | $175.15M | -$59.50M | -$1.84M | -$28.90M |
| Financing cash flow | -$19.91M | -$1.23M | -$1.03M | -$2.90M | -$13.44M |
| Depreciation & amortization | $14.23M | $9.34M | $8.11M | $13.12M | $15.40M |
| Stock-based compensation | $7.05M | $8.70M | $8.77M | $15.12M | $10.15M |
| Share buybacks | $9.74M | $0 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.